CROMA-PHARMA/CNBG
15.9.2020 15:02:14 CEST | Business Wire | Press release
Asia in general and China in particular represent the fastest growing aesthetic medicine markets worldwide. CNBG and Croma entered a far reaching, long-term cooperation combining each partner’s assets in a newly founded Joint Venture company to market Croma’s aesthetic products in China and Hong Kong. Financial details were not disclosed by the parties.
The cooperation between CNBG and Croma will in all probability have a major impact on the aesthetic medicine market in China, which had seen an average growth of over 20% annually within the past years. This caused an increasing demand for safe, high-quality products.
Croma will contribute its products, the currently approved Hyaluronic Acid Filler Princess® VOLUME and additional Filler products, as well as other facial aesthetic products of its range, whereas CNBG will provide its multi-channel distribution, marketing knowledge and synergistic products, in particular its botulinum toxin product Heng Li® , manufactured by the CNBG affiliate Lanzhou Biotechnique Development Co., Ltd. (“Lanzhou”).
The joint company aims to become a comprehensive supplier of minimally invasive aesthetic products in China, making effective use of the existing field force of Lanzhou. Sales of Princess® VOLUME will re-start very soon.
Xiangrong Li, Vice-president of CNBG said: “CNBG, via its affiliate Lanzhou, has been very successful for years with its botulinum toxin in China. Our search for suitable HA Filler products has finally come to an end – Croma indeed is the perfect partner and best possible fit for us. Together we are committed to shape and conquer the Chinese market with all its immense growth potential”.
Andreas Prinz, CCO and Co-Owner of Croma: "Croma incorporates more than 40 years of experience in R&D of viscoelastic products. Our fully automated production lines deliver 8 million pre-filled injectables per year. We are rightfully considered leading European experts in Hyaluronic Acid. With CNBG, we have found the perfect partner to merge our strengths and assets to successfully enter the fast-growing Chinese market. CNBG’s track-record and experience will heavily support Croma to sustainably prosper in Asia ."
About Croma-Pharma GmbH - leading experts in Hyaluronic Acid
Croma-Pharma, a family owned pharmaceutical company based in Austria is globally acclaimed for its expertise in pre-filled viscoelastic injectables for opthalmology, orthopaedics and aesthetic indications. Annual output of 8 million syringes makes Croma one of the major producers of high-end injectables worldwide. The success is based on research and development at the company headquarters in Austria. The owners follow a clear vision for high-quality technologies and boldly seize opportunities for the acquisition of complementary companies or technologies. Croma currently employs around 500 people and operates 12 affiliates in Europe, North-America, Brazil and Australia. Through distribution partnerships, its products are marketed in more than 70 countries all over the world. Croma is a multi-award winning company and celebrated its 40th anniversary in 2016.
About CNBG
CNBG is one of the largest Chinese biopharmaceutical companies and is the largest producer and supplier of vaccines and plasma-derived products in China. CNBG’s major business segments include human vaccines, blood products, medical aesthetics, veterinary vaccines, antibodies and diagnostics. Lanzhou is the sole producer of botulinum toxin in China. Heng Li® is the market leading botulinum toxin in the China market, with a market share of 75%, ranking No. 1 in the domestic market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005790/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 20268.3.2026 09:00:00 CET | Press release
From system-level software to end-to-end solutions, Aqara demonstrates how intelligent spaces are designed, operated, and scaled. Aqara, a global leader and pioneer in IoT, today unveiled its cutting-edge innovations in intelligent space technology at Light + Building 2026 (Hall 9.0, Booth A50). Aqara’s demonstration offers a glimpse into a comprehensive system that offers intelligent lighting control, energy saving, and space security experience for professional usage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308903989/en/ Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 2026 System-level Intelligent Control Aqara introduces a centralized system solution designed to streamline the management of building deployments at any scale. Moving beyond individual device control, Aqara offers a unified solution that provides architects, facility managers, and developers with
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom